More than $7.7 billion in drugs and medical supplies are still to be delivered for 2025, while an additional $2.172 billion in supplies are still outstanding for 2024.
This is according to the 2025 Report of the Auditor General on the Public Accounts of Guyana and the Accounts of Ministries, Departments and Regions, which was laid in the National Assembly on Wednesday.
In the report, it was explained that an initial sum of $17.197 billion was allocated to the Ministry of Health for the procurement of drugs and medical supplies for 2025, with an additional $2.394 billion transferred to the Ministry under the line item, bringing the total to $19.589 billion.
That entire sum was expended in 2025, according to the report, which also indicated that the Health Ministry entered into 197 contracts totaling $31.170 billion in 2025.
“At the time of reporting in September 2026, drugs and medical supplies valuing $23.373 billion were received, resulting in outstanding deliveries totaling $7.797 billion,” the report states.
The New GPC company accounts for a large chunk of that figure, with the records suggesting that it has failed to supply more than $6.2 billion in drugs and medical supplies for 2025. Additionally, Western Scientific Company has $1.422 billion in drugs and medical supplies outstanding, with Global Healthcare Supplies, Meditron Inc, and Massy Gas Products having millions of dollars in products outstanding.
In justifying the outstanding amounts, the Health Ministry explained that the contracts are multi-year contracts, with deliveries and payments extending across 2025 and 2026. It was further explained that “delivery and acceptance were affected by limited Material Management Unit (MMU) Bond storage capacity during 2025 and early 2026.
To address this situation, the Health Ministry has reportedly implemented the National Supply Chain Platform – CORTEXT – to improve visibility, coordination and management of procurement, warehousing, deliveries, and supplier performance.
But in addition to the more than $7 billion in supplies outstanding for 2025, the Audit Office found that $2.172 billion in drugs and medical supplies, from a total of 17 contracts, were still outstanding for 2024 as of September 2026.
Here again, New GPC accounted for more than $1.2 billion of the drugs and medical supplies still to be delivered, with Western Scientific also failing to supply hundreds of millions of dollars in drugs and medical supplies.
Again, the Health Ministry cited limited MMU Bond storage capacity during 2024, 2025 and early 2026 as the reason for the outstanding deliveries but assured that steps are being taken to address this deficiency.
In addition to drugs and medical supplies, the auditors also found that $695.192 million in capital items were still outstanding for 2026, and additional $22 million for 2024.
The Audit Office also found millions of dollars worth of expired and damaged drugs and medical supplies. It explained that at the time of reporting in September 2026, there were 229 instances of expired and damaged drugs and medical supplies at the MMU valuing $87.449 million.
It reported as well that a physical count for a sample of 30 drugs and medical items was conducted at the MMU, and it was two primary discrepancies were observed.
“There were excess/shortages between the physical count and the quantities stated on the schedule presented for 23 items and there were 16 instances where items were not at the location stated on the schedule. As a result, we were unable to determine the existence of such drugs,” the Audit Office explained.
The Health Ministry, in acknowledging the findings, again alluded to its use of CORTEX and assured that the digital supply chain management system will help to strengthen inventory management, visibility of stock levels and consumption, and more accurate monitoring and reconciliation of commodities issued to the regions.











You must be logged in to post a comment Login